Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.
adaptivemedical
Adaptive describes a strategy, process, or system that changes its behavior based on new information or shifting conditions. Like a thermostat that alters heating as the room temperature changes, an adaptive approach in finance or medicine can speed decisions, reduce waste, and manage risk by learning from results; for investors this can mean faster responses to market signals, more efficient use of capital, and potential changes in expected returns or uncertainty.
atopic dermatitismedical
A chronic inflammatory skin condition, often called eczema, that causes dry, itchy, red patches and recurring flare-ups; think of it as a persistent rash that can come and go over a person’s life. It matters to investors because its chronic nature and large patient population create steady demand for treatments, influence drug development and approval decisions, affect healthcare costs and reimbursement, and can drive revenue and valuation shifts for companies working on therapies and diagnostics.
biostatisticiantechnical
A biostatistician is a scientist who designs studies and analyzes medical or biological data to determine whether observed results are real or due to chance. They translate raw numbers from clinical trials, safety reports, and epidemiological studies into clear measures like effect sizes, confidence intervals, and risk estimates—like a referee or translator who tests the strength and reliability of evidence. Their work matters to investors because it affects how credible and actionable clinical and regulatory data appear.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--
Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced it will host a live webcast on Tuesday, July 7, 2026, to present key findings from the comprehensive interim analysis of its ongoing adaptive Phase 2 trial of GX-03 in atopic dermatitis.The Company will issue a press release tomorrow morning detailing these findings together with the optimized Stage 2 study design that will guide completion of the Phase 2 program.
Following the preliminary interim assessment announced in June, the Company conducted a detailed multi-week review of the Stage 1 dataset within the trial's adaptive framework. The review was overseen by Dr. Bruce Stouch, the study's lead biostatistician, and Dr. Stephen Hahn, Executive Clinical and Regulatory Lead, and evaluated efficacy and study design considerations to inform the design of Stage 2.
Webcast Details
Turn Therapeutics' live webcast will begin on Tuesday, July 7, 2026, at 4:30 p.m. ET. Bradley Burnam, Chief Executive Officer, and Dr. Hahn will host the call. The live webcast can be accessed via https://edge.media-server.com/mmc/p/jix773zk or the Investors section on the Company's website, https://ir.turntherapeutics.com. A replay of the webcast will be available following the call.
About Turn Therapeutics
Turn Therapeutics is a clinical-stage biotechnology company focused on developing targeted, localized therapies for inflammatory and infectious skin diseases. GX-03 is Turn Therapeutics' lead investigational topical candidate being developed as a targeted, non-systemic treatment for atopic dermatitis, designed to deliver biologic-level efficacy without the trade-offs of injectable administration or systemic immunosuppression.
